Senescent cells are cells that have permanently stopped dividing but haven't died; instead of disappearing, they linger and secrete a cocktail of inflammatory signalling molecules known as the senescence-associated secretory phenotype (SASP), which can push neighbouring healthy cells toward senescence too. This matters for hair specifically because the dermal papilla (DP), the structure at the base of the follicle that governs the hair growth cycle, is known to lose its hair-inductive capacity and accumulate senescent cells relatively quickly once removed and grown in laboratory culture.

Senolytics are compounds that selectively clear senescent cells rather than merely suppressing their inflammatory output, and they've generated real interest across ageing research generally, not just in hair. The two most-studied senolytics in this context are dasatinib, a prescription tyrosine kinase inhibitor used in cancer treatment, and quercetin, a naturally occurring flavonoid found in onions, apples, and many other plants. Fisetin, a related flavonoid found in strawberries, has separately been studied as a senolytic in its own right.

This is a genuinely well-designed piece of research from a credible hair biology lab, and it's the most direct preclinical evidence currently available linking senolytic treatment to restored hair-inductive function. It's worth being precise about exactly what it tested, though: human cells in a dish and in engineered constructs, plus a mouse implantation assay. No living person's scalp was treated with anything in this study, and the senolytic combination that worked best wasn't fisetin or quercetin alone, it was dasatinib, a prescription anticancer drug with a substantial adverse-effect profile, combined with quercetin.

Dasatinib carries a real, well-documented side effect profile, including fluid retention, cardiovascular effects, and bleeding risk, and is prescribed and monitored by an oncologist for a reason. It isn't available over the counter, and this study doesn't provide any basis for sourcing or self-administering it; we won't be covering how to do so, and would actively discourage it.

This is an independent finding, and it's worth being clear about how it differs from the Columbia study above rather than treating them as two data points for the same claim. The Kubo study didn't measure senescence, SASP, or senescent cell clearance at all; its proposed mechanism is TERT-driven bulge stem cell activation, a different pathway from the senolytic-depletion mechanism tested in dermal papilla cells. It also used topically applied fisetin directly on mouse skin, in a mouse model, not a human trial, and not the same cell type (DP cells) the Columbia senescence study focused on.

Put simply: fisetin has a real, independently documented hair-growth signal in mice, via a mechanism distinct from the senolytic-clearance mechanism tested in the Columbia study. That's a legitimate reason for interest in fisetin specifically. It isn't the same evidence as the senolytic-clearance story, even though the two get folded together constantly in secondary coverage.

Three separate, real findings, senolytic clearance restoring DP hair-inductive capacity (D+Q, human cells, in vitro and mouse implantation), fisetin activating TERT and inducing anagen in mouse skin, and fisetin's general senotherapeutic profile in aged mice, get routinely compressed into a single claim: "take fisetin and quercetin supplements to clear senescent cells from your scalp and regrow hair." None of the individual studies say that.

The specific senolytic combination that actually restored hair-inductive function in dermal papilla cells used dasatinib, a prescription drug, not an over-the-counter supplement stack. Quercetin has not been demonstrated to reproduce that result on its own; the hair-specific evidence is for the combination of dasatinib and quercetin, not quercetin as an isolated intervention. The study that used fisetin alone and produced a hair-growth signal did so through a completely different, non-senolytic mechanism, in mice, applied topically to skin, not taken orally. We found no study testing oral fisetin and quercetin supplementation, at any dose, against human hair outcomes, and no study testing whether oral supplementation reaches scalp tissue at concentrations anywhere near what was used in these cell culture and topical animal experiments.

We're not covering senolytic supplementation protocols, dosing, or cycling schedules here, including the informal "senolytic stacking" approaches circulating in longevity and biohacking communities, some of which involve sourcing prescription-only drugs like dasatinib outside a clinical setting. That's a real practice we're aware exists, and one we'd actively discourage rather than provide any guidance toward.

Cellular senescence in the dermal papilla is a genuinely interesting, credibly-researched mechanism relevant to hair follicle ageing, and clearing senescent DP cells has been shown to restore hair-inductive capacity, in cell culture and mouse implantation models. Fisetin separately has a real, independently documented hair-growth effect in mice via TERT activation, through a mechanism distinct from senescence clearance. Neither finding has been tested in a human hair trial, and the specific senolytic approach that performed best in the most relevant study included a prescription drug that was being investigated in a preclinical research setting, not as a hair-loss treatment in humans.

This research sits in a different lane from the actives AmpleLab formulates with; none of our products target cellular senescence or TERT activation, and we're not positioning anything we sell as related to this mechanism. We're covering it because it's a genuinely active, credible area of hair research that our audience is likely to encounter, and because the gap between what's been studied and what's being claimed online is worth closing honestly.

This article is provided for educational purposes and does not constitute medical advice. AmpleLab does not sell or endorse any senolytic supplement or compound, and does not provide guidance on sourcing, dosing, or using prescription medications outside clinical supervision. Consult a GP before starting any new supplement.

AmpleLab.